Do analysts prefer ATHX or ARTL?

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Artelo Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ATHX or ARTL more profitable?

Athersys' return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Artelo Biosciences N/A -518.27% -194.29%

Do analysts recommend ATHX or NXTS?

Given Athersys' higher probable upside, equities analysts plainly believe Athersys is more favorable than Nexentis Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nexentis Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATHX or NXTS more profitable?

Athersys' return on equity of 0.00% beat Nexentis Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Nexentis Technologies N/A -304.79% -178.91%

Do analysts rate CASI or ATHX?

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than CASI Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CASI or ATHX more profitable?

Athersys has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% Athersys N/A N/A -223.03%

Do analysts rate ATHX or CANF?

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,772.34%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Athersys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athersys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ATHX or CANF more profitable?

Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Can-Fite BioPharma N/A N/A N/A

Which has preferable valuation & earnings, ATHX or ORGS?

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athersys $146K 0.00 -$72.53M -$2.03 N/A Orgenesis $662K 0.26 -$55.36M -$11.51 N/A

Is ATHX or ORGS more profitable?

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Athersys N/A N/A -223.03% Orgenesis -3,827.81% N/A -130.18%

Athersys (ATHX) Competitors

Compare

ATHX vs. ARTL, NXTS, CASI, CANF, and ORGS

Should you buy Athersys stock or one of its competitors? Athersys's main competitors and comparable companies include Artelo Biosciences (ARTL), Nexentis Technologies (NXTS), CASI Pharmaceuticals (CASI), Can-Fite BioPharma (CANF), and Orgenesis (ORGS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Athersys compare to Artelo Biosciences?

Athersys (NASDAQ:ATHX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Athersys has a beta of -0.9, indicating that its share price is 190% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

19.4% of Athersys shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 0.0% of Athersys shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Athersys' return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Artelo Biosciences	N/A	-518.27%	-194.29%

Given Athersys' higher possible upside, analysts clearly believe Athersys is more favorable than Artelo Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Artelo Biosciences had 2 more articles in the media than Athersys. MarketBeat recorded 2 mentions for Artelo Biosciences and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.50 indicating that Athersys is being referred to more favorably in the media.

Company	Overall Sentiment
Athersys	Neutral
Artelo Biosciences	Negative

Artelo Biosciences has lower revenue, but higher earnings than Athersys. Artelo Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$16.80	N/A

Summary

Athersys beats Artelo Biosciences on 7 of the 13 factors compared between the two stocks.

How does Athersys compare to Nexentis Technologies?

Athersys (NASDAQ:ATHX) and Nexentis Technologies (NASDAQ:NXTS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Athersys has a beta of -0.9, suggesting that its share price is 190% less volatile than the broader market. Comparatively, Nexentis Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

19.4% of Athersys shares are owned by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are owned by institutional investors. 0.0% of Athersys shares are owned by company insiders. Comparatively, 6.5% of Nexentis Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Given Athersys' higher probable upside, equities analysts plainly believe Athersys is more favorable than Nexentis Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nexentis Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Athersys' return on equity of 0.00% beat Nexentis Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Nexentis Technologies	N/A	-304.79%	-178.91%

In the previous week, Nexentis Technologies had 1 more articles in the media than Athersys. MarketBeat recorded 1 mentions for Nexentis Technologies and 0 mentions for Athersys. Athersys' average media sentiment score of 0.00 equaled Nexentis Technologies'average media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Nexentis Technologies	Neutral

Nexentis Technologies has higher revenue and earnings than Athersys. Nexentis Technologies is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Nexentis Technologies	$210K	11.60	-$4M	-$96.07	N/A

Summary

Nexentis Technologies beats Athersys on 8 of the 12 factors compared between the two stocks.

How does Athersys compare to CASI Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Athersys (NASDAQ:ATHX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

Athersys has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Athersys	N/A	N/A	-223.03%

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Athersys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market.

Given Athersys' higher probable upside, analysts clearly believe Athersys is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CASI Pharmaceuticals has higher revenue and earnings than Athersys. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A

In the previous week, CASI Pharmaceuticals' average media sentiment score of 0.00 equaled Athersys'average media sentiment score.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Athersys	Neutral

Summary

CASI Pharmaceuticals beats Athersys on 7 of the 11 factors compared between the two stocks.

How does Athersys compare to Can-Fite BioPharma?

Athersys (NASDAQ:ATHX) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Athersys has a beta of -0.9, suggesting that its stock price is 190% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the broader market.

19.4% of Athersys shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Can-Fite BioPharma has higher revenue and earnings than Athersys. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Can-Fite BioPharma	$405K	3.80	-$7.63M	-$22.80	N/A

In the previous week, Can-Fite BioPharma had 4 more articles in the media than Athersys. MarketBeat recorded 4 mentions for Can-Fite BioPharma and 0 mentions for Athersys. Can-Fite BioPharma's average media sentiment score of 0.20 beat Athersys' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Athersys	Neutral
Can-Fite BioPharma	Neutral

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 1,772.34%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Athersys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Can-Fite BioPharma	N/A	N/A	N/A

Summary

Can-Fite BioPharma beats Athersys on 11 of the 13 factors compared between the two stocks.

How does Athersys compare to Orgenesis?

Athersys (NASDAQ:ATHX) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

19.4% of Athersys shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Athersys has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Orgenesis	-3,827.81%	N/A	-130.18%

Orgenesis has higher revenue and earnings than Athersys. Orgenesis is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146K	0.00	-$72.53M	-$2.03	N/A
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A

Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, meaning that its stock price is 216% more volatile than the broader market.

In the previous week, Athersys' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Athersys	Neutral
Orgenesis	Neutral

Summary

Orgenesis beats Athersys on 6 of the 9 factors compared between the two stocks.

Get Athersys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHX vs. The Competition

Export

Metric	Athersys	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$833K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.28	273.30	25.25
Price / Sales	N/A	755.95	618.15	97.66
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	N/A	12.32	12.89	6.14
Net Income	-$72.53M	$2.82B	$3.47B	$349.01M

Athersys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHX Athersys	N/A	N/A	N/A	N/A	$833K	$146K	N/A	24
ARTL Artelo Biosciences	0.9061 of 5 stars	$0.64 -10.5%	N/A	-97.4%	$2.92M	N/A	N/A	5
NXTS Nexentis Technologies	0.2525 of 5 stars	$1.82 -3.5%	N/A	-96.8%	$2.63M	$210K	N/A	2	News Coverage Positive News Gap Up
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
CANF Can-Fite BioPharma	2.2373 of 5 stars	$3.36 +1.2%	$44.00 +1,209.1%	-82.2%	$2.20M	$405K	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHX) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athersys (ATHX) Competitors

ATHX vs. ARTL, NXTS, CASI, CANF, and ORGS

How does Athersys compare to Artelo Biosciences?

Summary

How does Athersys compare to Nexentis Technologies?

Summary

How does Athersys compare to CASI Pharmaceuticals?

Summary

How does Athersys compare to Can-Fite BioPharma?

Summary

How does Athersys compare to Orgenesis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athersys (ATHX) Competitors

ATHX vs. ARTL, NXTS, CASI, CANF, and ORGS

How does Athersys compare to Artelo Biosciences?

Which has more risk & volatility, ATHX or ARTL?

Do insiders and institutionals hold more shares of ATHX or ARTL?

Is ATHX or ARTL more profitable?

Do analysts prefer ATHX or ARTL?

Does the media favor ATHX or ARTL?

Which has stronger valuation and earnings, ATHX or ARTL?

Summary

How does Athersys compare to Nexentis Technologies?

Which has more risk and volatility, ATHX or NXTS?

Do institutionals & insiders hold more shares of ATHX or NXTS?

Do analysts recommend ATHX or NXTS?

Is ATHX or NXTS more profitable?

Does the media favor ATHX or NXTS?

Which has preferable earnings & valuation, ATHX or NXTS?

Summary

How does Athersys compare to CASI Pharmaceuticals?

Is CASI or ATHX more profitable?

Do insiders & institutionals hold more shares of CASI or ATHX?

Which has more risk & volatility, CASI or ATHX?

Do analysts rate CASI or ATHX?

Which has preferable earnings and valuation, CASI or ATHX?

Does the media refer more to CASI or ATHX?

Summary

How does Athersys compare to Can-Fite BioPharma?

Which has more risk & volatility, ATHX or CANF?

Do insiders & institutionals hold more shares of ATHX or CANF?

Which has higher earnings and valuation, ATHX or CANF?

Does the media prefer ATHX or CANF?

Do analysts rate ATHX or CANF?

Is ATHX or CANF more profitable?

Summary

How does Athersys compare to Orgenesis?

Do insiders & institutionals believe in ATHX or ORGS?

Is ATHX or ORGS more profitable?

Which has preferable valuation & earnings, ATHX or ORGS?

Which has more risk and volatility, ATHX or ORGS?

Does the media refer more to ATHX or ORGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHX vs. The Competition

Athersys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools